InvestSMART

Telix Pharmaceuticals Limited (ASX: TLX) - Announcements

- Current share price for TLX : $16.450

ASX company news and announcements for Telix Pharmaceuticals Limited (TLX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Telix Pharmaceuticals Limited (TLX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Telix Pharmaceuticals Limited (TLX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Telix Pharmaceuticals Limited (TLX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$5,589 2020 Annual Report 26 Feb 2021 9:06AM $3.930 $16.450 risen by 318.58%
$5,589 Appendix 4E - Results for announcement to the market 26 Feb 2021 9:01AM $3.930 $16.450 risen by 318.58%
$5,589 Corporate Governance Statement year ended 31 December 2020 26 Feb 2021 8:58AM $3.930 $16.450 risen by 318.58%
$5,589 Appendix 4G - key to governance disclosures 26 Feb 2021 8:57AM $3.930 $16.450 risen by 318.58%
$5,589 Shareholder update - year ended 31 December 2020 26 Feb 2021 7:47AM $3.930 $16.450 risen by 318.58%
$5,589 PMDA clearance to commence Prostate Cancer Imaging Study 22 Feb 2021 8:24AM $4.130 $16.450 risen by 298.31%
$5,589 Czech Republic Grants National Authorisation for TLX591 Kit 16 Feb 2021 8:14AM $4.120 $16.450 risen by 299.27%
$5,589 Notification of Conference Call for FY2020 Results 16 Feb 2021 8:14AM $4.120 $16.450 risen by 299.27%
$5,589 Collaboration with Heidelberg University Hospital 10 Feb 2021 8:22AM $4.400 $16.450 risen by 273.86%
$5,589 Telix Pursues Direct Benelux Product Distribution 8 Feb 2021 8:26AM $4.190 $16.450 risen by 292.60%
$5,589 Appendix 3G - issue of unlisted share options 29 Jan 2021 8:49AM $4.030 $16.450 risen by 308.19%
$5,589 Appendix 4C and Activities Report for December 2020 Quarter 29 Jan 2021 8:43AM $4.030 $16.450 risen by 308.19%
$5,589 First US patients dosed in Ph III ZIRCON trial 25 Jan 2021 9:02AM $4.530 $16.450 risen by 263.13%
$5,589 TLX101 Glioblastoma Therapy - Clinical Update 23 Dec 2020 8:24AM $3.880 $16.450 risen by 323.97%
$5,589 Cleansing Notice under section 708A Corporations Act 17 Dec 2020 8:23AM $3.560 $16.450 risen by 362.08%
$5,589 Appendix 2A - issue of shares from exercise of options 17 Dec 2020 8:22AM $3.560 $16.450 risen by 362.08%
$5,589 Change in substantial holding 17 Dec 2020 8:19AM $3.560 $16.450 risen by 362.08%
$5,589 New Drug Submission filed with Health Canada for TLX591-CDx 16 Dec 2020 9:05AM $3.510 $16.450 risen by 368.66%
$5,589 Urologic Oncology Alliance with Mauna Kea Technologies 16 Dec 2020 8:21AM $3.510 $16.450 risen by 368.66%
$5,589 IP Agreement with U Southampton for access to TRALA data 14 Dec 2020 8:33AM $3.750 $16.450 risen by 338.67%
$5,589 Cleansing Notice under section 708A Corporations Act 14 Dec 2020 8:24AM $3.750 $16.450 risen by 338.67%
$5,589 Appendix 2A - issue of shares from exercise of options 14 Dec 2020 8:24AM $3.750 $16.450 risen by 338.67%
$5,589 Appendix 2A - shares issued as consideration for acquisition 14 Dec 2020 8:23AM $3.750 $16.450 risen by 338.67%
$5,589 Telix Completes Acquisition of TheraPharm GmbH 14 Dec 2020 8:23AM $3.750 $16.450 risen by 338.67%
$5,589 Telix and Kanazawa University Phase I trial of TLX591-CDx 14 Dec 2020 8:23AM $3.750 $16.450 risen by 338.67%

651 - 675 of 948 results

Page 27 of 38

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.